LX 9211

Drug Profile

LX 9211

Alternative Names: LX-9211

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb; Lexicon Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Adaptor-associated-kinase-1-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neuropathic pain

Most Recent Events

  • 27 Sep 2017 Phase-I clinical trials in Neuropathic pain (In volunteers) (PO)
  • 27 Sep 2017 Lexicon Pharmaceuticals files an IND application with the US FDA for a phase I trial in Healthy volunteers in Neuropathic pain (PO) before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top